Xencor, Inc.

Xencor, Inc.verified

XNCR

Price:

$20.85

Market Cap:

$1.46B

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat m...[Read more]

Industry

Biotechnology

IPO Date

2013-12-03

Stock Exchange

NASDAQ

Ticker

XNCR

The Enterprise Value as of September 2024 (TTM) for Xencor, Inc. (XNCR) is 1.51B

According to Xencor, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.51B. This represents a change of 16.96% compared to the average of 1.30B of the last 4 quarters.

Xencor, Inc. (XNCR) Historical Enterprise Value (quarterly & annually)

How has XNCR Enterprise Value performed in the past?

The mean historical Enterprise Value of Xencor, Inc. over the last ten years is 1.44B. The current 1.51B Enterprise Value has changed 10.45% with respect to the historical average. Over the past ten years (40 quarters), XNCR's Enterprise Value was at its highest in in the June 2019 quarter at 2.46B. The Enterprise Value was at its lowest in in the September 2014 quarter at 231.37M.

Quarterly (TTM)
Annual

Average

1.44B

Median

1.44B

Minimum

448.86M

Maximum

2.34B

Xencor, Inc. (XNCR) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Xencor, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 115.16%

Maximum Annual Enterprise Value = 2.34B

Minimum Annual Increase = -30.17%

Minimum Annual Enterprise Value = 448.86M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20231.31B-15.71%
20221.56B-30.17%
20212.23B-4.76%
20202.34B23.09%
20191.90B-0.66%
20181.92B89.88%
20171.01B-5.78%
20161.07B92.11%
2015557.81M24.27%
2014448.86M115.16%

Xencor, Inc. (XNCR) Average Enterprise Value

How has XNCR Enterprise Value performed in the past?

The current Enterprise Value of Xencor, Inc. (XNCR) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

1.70B

5-year avg

1.87B

10-year avg

1.44B

Xencor, Inc. (XNCR) Enterprise Value vs. Peers

How is XNCR’s Enterprise Value compared to its peers?

Xencor, Inc.’s Enterprise Value is less than Edgewise Therapeutics, Inc. (1.75B), less than Keros Therapeutics, Inc. (1.70B), greater than Monte Rosa Therapeutics, Inc. (300.68M), greater than Mineralys Therapeutics, Inc. (513.45M), greater than Erasca, Inc. (697.60M), less than Kura Oncology, Inc. (1.52B), less than Protagonist Therapeutics, Inc. (2.29B), less than Merus N.V. (2.75B), greater than Replimune Group, Inc. (681.29M), less than Cerevel Therapeutics Holdings, Inc. (8.24B), less than IDEAYA Biosciences, Inc. (2.75B), greater than AnaptysBio, Inc. (1.41B), greater than MeiraGTx Holdings plc (319.63M), greater than Homology Medicines, Inc. (-103303255.00), less than Nuvalent, Inc. (6.57B), less than DICE Therapeutics, Inc. (2.21B), less than Arcellx, Inc. (4.30B), less than Vaxcyte, Inc. (13.70B), greater than Viridian Therapeutics, Inc. (1.26B), greater than Larimar Therapeutics, Inc. (410.36M), greater than Syndax Pharmaceuticals, Inc. (1.43B), greater than Sutro Biopharma, Inc. (423.40M),

Build a custom stock screener for Xencor, Inc. (XNCR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xencor, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xencor, Inc. (XNCR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xencor, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Xencor, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Xencor, Inc. (XNCR)?

What is the 3-year average Enterprise Value for Xencor, Inc. (XNCR)?

What is the 5-year average Enterprise Value for Xencor, Inc. (XNCR)?

How does the current Enterprise Value for Xencor, Inc. (XNCR) compare to its historical average?